1AD Share Price Performance
AU$0.004
-0.01 (-76.47%)
Price AU$0.004
Share Pricen/a
AdAlta Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
1AD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
AdAlta Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.0027
- 67.58%
- -665.02%
- -304.7%
About 1AD
- Founded
- 2006
- Employees
- 1
- CEO
- WebsiteView website
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University. The company was incorporated in 2006 and is based in Camberwell, Australia.
